Table 2.
Silk-based drug delivery systems for cancer therapy.
| Silk biomaterial | Preparatiom method | Drug/route of administration | Target | Cell line/in vivo model | References |
|---|---|---|---|---|---|
| B. mori silk film | Film casting with water vapor annealing | Doxorubicin/intratumoral | Breast cancer | MDA-MB-231/orthotopic adrenal tumor xenograft in mice | 15,24 |
| B. mori silk hydrogel | Self-assembly mediated by sonication | Doxorubicin/intratumoral | Breast cancer | MDA-MB-231, MCF-7/tumor xenograft in mice | 16 |
| B. mori silk particle | Self-assembly with paclitaxel solution in ethanol | Paclitaxel/intratumoral | Gastric cancer | BCG-823/tumor xenograft in mice | 20 |
| B. mori silk particle | Desolvation method with acetone | Doxorubicin | Breast cancer | MCF-7/n/a | 18 |
| B. mori silk-albumin particle | Desolvation with acetone and crosslinking with glutaraldehyde | Metotrexate | Breast cancer | MDA-MB-231/n/a | 21 |
| B. mori silk fibroin particle and silk fibroin-chitosan particles | The microdot capillary method, lyophilization, methanol treatment | Curcumin | Breast cancer, melanoma | MCF-7, MDA-MB-453/n/a | 22 |
| B. mori silk film coated liposome | Lyophilization of silk fibroin with emodin-loaded liposomes and methanol treatment | Emodin | Breast cancer, melanoma | MCF-7, MDA-MB-453, BT-474/n/a | 17,30 |
| Bioengineered silk fibroin–elastin-like particle | Self-assembly with hydrophobic doxorubicin | Doxorubicin | Cervical cancer | HeLa/n/a | 34 |
| Bioengineered functionalized spider silk sphere | Salting-out with potassium phosphate | Doxorubicin | Her2/neu overexpressing ovarian and breast cancer | SKOV3, SKBR3/n/a | 40 |
| Bioengineered spider silk and DNA complexes | Self- assembly with DNA | Plasmid DNA/intravenous | Breast cancer, melanoma | MDA-MB-231, MDA-MB-435/tumor xenograft in mice | 38,39 |